Merck Leads Rebound In Rx Stocks; Upbeat Finish To Historic Bad Year
Merck's fourth quarter rebound suggests that Wall Street may be looking on the bright side for pharmaceutical stocks at last
You may also be interested in...
Sponsors of hormone replacement therapies have two months to pull together data to justify exemptions to FDA's proposed class labeling incorporating risk information from the Women's Health Initiative
Merck is telling investors to expect a "meaningful" Medicare prescription drug benefit in the 108th Congress
Refinements to pharmaceutical industry pipelines during the Clinton healthcare reform era are about to pay off in a wave of new product launches, Pfizer CEO Hank McKinnell told investors at the Bear Stearns healthcare conference in New York City Sept. 17